BAKER BROS. ADVISORS LP
Q4 2022 13F-HR Holdings
Net value change ($000)
+1,381,937
(9.1%)
New positions
14
Sold out positions
16
Turnover %
3.8%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q3 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ONC | 993,256 | 63.1% |
| INCY | 494,626 | 20.5% |
| MDGL | 351,035 | 360.3% |
| BMRN | 142,656 | 22.1% |
| ASND | 104,051 | 20.8% |
| REPL | 57,282 | 85.2% |
| Horizon Therapeutics Public Ltd Co | 50,339 | 83.9% |
| AKRO | 49,144 | 60.9% |
| SpringWorks Therapeutics, Inc. | 39,757 | NEW |
| RYTM | 36,510 | 24.6% |
Top Reduces (Value $000, Stocks/ETFs)
| Seagen Inc. | -390,310 | -6.1% |
| Global Blood Therapeutics, Inc. | -254,183 | -100.0% |
| ChemoCentryx, Inc. | -92,609 | -100.0% |
| TVTX | -55,545 | -68.3% |
| Forma Therapeutics Holdings, Inc. | -37,641 | -100.0% |
| Mirati Therapeutics, Inc. | -34,582 | -35.1% |
| Verve Therapeutics, Inc. | -21,248 | -43.7% |
| ACAD | -18,446 | -2.7% |
| RLMD | -18,329 | -100.0% |
| ALKERMES PLC | -18,199 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|